Background: COVID 19 pandemic has significantly affected the mental health of patients, especially along with the lockdown crisis. The aim of this study was to assess the prevalence and determinants associated with depression and anxiety among the patients admitted with moderate COVID 19 in our hospital. Materials and Methods: It was a cross sectional descriptive study done in 100 admitted cases above 18 years of age. A predesigned proforma was filled along with laboratory investigations in fasting state. Hospital Anxiety and Depression Scale (HADS score) was used for the assessment of mental health of these patients. Results: Out of 100 admitted cases with moderate grade severity of COVID-19, the prevalence of anxiety and depression was found to be 31.25% and 47.4% respectively. Both anxiety and depression were found to be associated with low oxygen saturation (less than 85% on room air, higher class of steroids and anticoagulation respectively. Depression was also found to be associated with higher blood sugar and serum creatinine. Anxiety was found to have a direct correlation with high blood sugar, serum transaminases and serum ferritin levels and inverse relationship with use of the drug, ivermectin (p<0.027). Conclusion: Our study proves that there is a high prevalence of anxiety and depression in patients with COVID-19. Ivermectin should be a part of treatment of all moderate (or may be mild) cases suffering with this disease.

">

Background: COVID 19 pandemic has significantly affected the mental health of patients, especially along with the lockdown crisis. The aim of this study was to assess the prevalence and determinants associated with depression and anxiety among the patients admitted with moderate COVID 19 in our hospital. Materials and Methods: It was a cross sectional descriptive study done in 100 admitted cases above 18 years of age. A predesigned proforma was filled along with laboratory investigations in fasting state. Hospital Anxiety and Depression Scale (HADS score) was used for the assessment of mental health of these patients. Results: Out of 100 admitted cases with moderate grade severity of COVID-19, the prevalence of anxiety and depression was found to be 31.25% and 47.4% respectively. Both anxiety and depression were found to be associated with low oxygen saturation (less than 85% on room air, higher class of steroids and anticoagulation respectively. Depression was also found to be associated with higher blood sugar and serum creatinine. Anxiety was found to have a direct correlation with high blood sugar, serum transaminases and serum ferritin levels and inverse relationship with use of the drug, ivermectin (p<0.027). Conclusion: Our study proves that there is a high prevalence of anxiety and depression in patients with COVID-19. Ivermectin should be a part of treatment of all moderate (or may be mild) cases suffering with this disease.

">

Background: COVID 19 pandemic has significantly affected the mental health of patients, especially along with the lockdown crisis. The aim of this study was to assess the prevalence and determinants associated with depression and anxiety among the patients admitted with moderate COVID 19 in our hospital. Materials and Methods: It was a cross sectional descriptive study done in 100 admitted cases above 18 years of age. A predesigned proforma was filled along with laboratory investigations in fasting state. Hospital Anxiety and Depression Scale (HADS score) was used for the assessment of mental health of these patients. Results: Out of 100 admitted cases with moderate grade severity of COVID-19, the prevalence of anxiety and depression was found to be 31.25% and 47.4% respectively. Both anxiety and depression were found to be associated with low oxygen saturation (less than 85% on room air, higher class of steroids and anticoagulation respectively. Depression was also found to be associated with higher blood sugar and serum creatinine. Anxiety was found to have a direct correlation with high blood sugar, serum transaminases and serum ferritin levels and inverse relationship with use of the drug, ivermectin (p<0.027). Conclusion: Our study proves that there is a high prevalence of anxiety and depression in patients with COVID-19. Ivermectin should be a part of treatment of all moderate (or may be mild) cases suffering with this disease.

"> Determinants of Anxiety and Depression in Patients with Covid 19 Admitted in a Tertiary Care Hospital of New Delhi, India » The International Journal of Indian Psychȯlogy

OPEN ACCESS

PEER-REVIEWED

Original Study

| Published: August 03, 2021

Determinants of Anxiety and Depression in Patients with Covid 19 Admitted in a Tertiary Care Hospital of New Delhi, India

Pulin Kumar Gupta

Professor, Department of Medicine, ABVIMS, Dr RML Hospital, New Delhi, India Google Scholar More about the auther

, Sanjeet Panesar

Assistant Professor, Department of Community Medicine, ABVIMS, Dr RML Hospital, New Delhi, India Google Scholar More about the auther

, MPS Chawla

Professor, Department of Medicine, ABVIMS, Dr RML Hospital, New Delhi, India. Google Scholar More about the auther

, Princi Jain

Assistant Professor, Department of Medicine, ABVIMS, Dr RML Hospital, New Delhi, India. Google Scholar More about the auther

, Shrinivas Murthy

Professor, Department of Medicine, ABVIMS, Dr RML Hospital, New Delhi, India. Google Scholar More about the auther

, Om Prakash

Resident, Department of Medicine, ABVIMS, Dr RML Hospital, New Delhi, India. Google Scholar More about the auther

, Sunil Mangla

Resident, Department of Medicine, ABVIMS, Dr RML Hospital, New Delhi, India. Google Scholar More about the auther

, Gurmeet Kaur

Associate Professor, Department of Medicine, ABVIMS, Dr RML Hospital, New Delhi, India. Google Scholar More about the auther

DIP: 18.01.042.20210903

DOI: 10.25215/0903.042

ABSTRACT

Background: COVID 19 pandemic has significantly affected the mental health of patients, especially along with the lockdown crisis. The aim of this study was to assess the prevalence and determinants associated with depression and anxiety among the patients admitted with moderate COVID 19 in our hospital. Materials and Methods: It was a cross sectional descriptive study done in 100 admitted cases above 18 years of age. A predesigned proforma was filled along with laboratory investigations in fasting state. Hospital Anxiety and Depression Scale (HADS score) was used for the assessment of mental health of these patients. Results: Out of 100 admitted cases with moderate grade severity of COVID-19, the prevalence of anxiety and depression was found to be 31.25% and 47.4% respectively. Both anxiety and depression were found to be associated with low oxygen saturation (less than 85% on room air, higher class of steroids and anticoagulation respectively. Depression was also found to be associated with higher blood sugar and serum creatinine. Anxiety was found to have a direct correlation with high blood sugar, serum transaminases and serum ferritin levels and inverse relationship with use of the drug, ivermectin (p<0.027). Conclusion: Our study proves that there is a high prevalence of anxiety and depression in patients with COVID-19. Ivermectin should be a part of treatment of all moderate (or may be mild) cases suffering with this disease.

Download Full Text
Responding Author Information

Princi Jain @ princuja@gmail.com

Find On

Article Overview

ISSN 2348-5396

ISSN 2349-3429

18.01.042.20210903

10.25215/0903.042

Download: 7

View: 82

Published in   Volume 09, Issue 3, July- September, 2021